Compare BioNano Genomics Inc (BNGO) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Genuine Parts Company — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Genuine Parts Company trades at $133.46 (market cap $18.62B). The key difference: Genuine Parts Company is far larger — about 1363.1× BioNano Genomics Inc's market cap, and Genuine Parts Company pays a 3.15% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | GPC | |
|---|---|---|
Market Cap | $13.66M | $18.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $149.26 |
52-Week Low | $1.06 | $92.47 |
Enterprise Value | $16.26M | $24.72B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
GPC trades at $133.47, down 0.8% today, with a bullish technical trend and strong institutional support. Recent Q2 2026 earnings beat estimates with EPS of $2.15 versus $2.08 expected, driven by 6% sales growth. The stock is near its 52-week high, supported by a consensus price target of $148.67, though net income margins remain thin at 0.13%.
Outlook is positive with analyst consensus leaning buy, but risks include compressed profitability and high P/E ratio. The dividend yield adds income appeal, yet margin pressures from inflation and competition warrant caution for growth-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
